Recent News

• 11.24.2025 - VP, Head of Biometrics
• 11.21.2025 - LPA-Induced Activation of Satellite Glial Cells and Its Modulation by PIPE-791, a novel LPA1 antagonist, in an In Vitro Pain Model
• 11.21.2025 - LPA1 receptor binding sites are abundant in multiple sclerosis patient rim lesions associated with TSPO activation and disease progression
• 11.21.2025 - CNS-Penetrant LPA₁ Antagonist PIPE-791 Provides Superior Analgesia Compared to Peripherally-Restricted CTX-343 in a Rat Model of LPA-Induced Osteoarthritis
• 09.18.2025 - Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
• 09.09.2025 - Baird 2025 Global Healthcare Conference
• 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.04.2025 - Cantor Global Healthcare Conference 2025
• 09.03.2025 - The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis
• 08.28.2025 - Contineum Therapeutics to Present at September Investor Conferences

Recent Filings

• 11.20.2025 - 8-K Current report
• 11.20.2025 - EX-99.1 EX-99.1
• 11.04.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.30.2025 - 8-K Current report
• 09.18.2025 - 8-K Current report
• 09.18.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors